|
Minerva Neurosciences, Inc. (Nerv) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Minerva Neurosciences, Inc. (NERV) Bundle
Entdecken Sie die finanziellen Aussichten von Minerva Neurosciences, Inc. (Nerv) mit unserem benutzerfreundlichen DCF-Taschenrechner! Geben Sie Ihre Projektionen für Wachstum, Margen und Kosten ein, um den inneren Wert von Minerva Neurosciences, Inc. (Nerv) zu berechnen und Ihren Investitionsansatz zu verfeinern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -100 | 0 | 0 | 0 | -25 | -25 | -25 | -25 | -25 |
| EBITDA | 1.9 | -51.6 | -24.7 | -21.7 | -21,848.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 4.68 | 100 | 100 | 100 | 100 | 80.94 | 80.94 | 80.94 | 80.94 | 80.94 |
| Depreciation | .2 | .1 | .0 | .0 | -21,826.5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 0.42787 | 100 | 100 | 100 | 100 | 80.09 | 80.09 | 80.09 | 80.09 | 80.09 |
| EBIT | 1.8 | -51.7 | -24.7 | -21.7 | -21.8 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 4.26 | 100 | 100 | 100 | 100 | 80.85 | 80.85 | 80.85 | 80.85 | 80.85 |
| Total Cash | 25.4 | 60.8 | 36.1 | 41.0 | 21,362.0 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 3.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 100 | 100 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
| Inventories | .0 | .0 | -3.0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 100 | 100 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | 1.0 | 1.9 | 1.0 | 1.8 | 1.6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 2.42 | 100 | 100 | 100 | 100 | 80.48 | 80.48 | 80.48 | 80.48 | 80.48 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 0 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 | 99.9 |
| EBITAT | 1.8 | -49.9 | -30.0 | -21.7 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 2.9 | -48.9 | -31.0 | -20.8 | -21,826.8 | -1.6 | .0 | .0 | .0 | .0 |
| WACC, % | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -21 | |||||||||
| Equity Value | 20 | |||||||||
| Diluted Shares Outstanding, MM | 8 | |||||||||
| Equity Value Per Share | 2.62 |
What You Will Get
- Real Minerva Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Minerva Neurosciences, Inc. (NERV).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Minerva.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Minerva’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Minerva Neurosciences, Inc. (NERV).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Minerva.
Key Features
- Customizable Forecast Inputs: Adjust essential variables such as revenue growth, EBITDA %, and capital expenditures for accurate modeling.
- Instant DCF Valuation: Automatically computes intrinsic value, NPV, and other financial metrics in real time.
- High Precision Analytics: Leverages Minerva Neurosciences' (NERV) actual financial data for dependable valuation results.
- Simplified Scenario Analysis: Effortlessly evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Streamlines the valuation process, removing the need for intricate model construction from the ground up.
How It Works
- Download the Template: Gain immediate access to the Excel-based NERV DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
- Instant Calculations: The model automatically recalculates Minerva Neurosciences' intrinsic value.
- Test Scenarios: Explore different assumptions to assess potential valuation shifts.
- Analyze and Decide: Utilize the results to inform your investment or financial evaluation.
Why Choose This Calculator for Minerva Neurosciences, Inc. (NERV)?
- Designed for Experts: A sophisticated tool utilized by healthcare analysts, investors, and financial advisors.
- Comprehensive Data: Minerva’s historical and anticipated financials preloaded for precision.
- Forecast Scenarios: Effortlessly simulate various projections and assumptions.
- Detailed Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance simplifies the entire calculation process.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Minerva Neurosciences, Inc. (NERV) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to Minerva Neurosciences, Inc. (NERV).
- Consultants: Deliver professional valuation insights on Minerva Neurosciences, Inc. (NERV) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like Minerva Neurosciences, Inc. (NERV) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Minerva Neurosciences, Inc. (NERV).
What the Template Contains
- Pre-Filled Data: Includes Minerva Neurosciences' historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Minerva Neurosciences' profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.